PCVXVaxcyte, Inc.
$71.34+125% 1Y
$71.34
$32.1452 weeks$71.34
Latest close: a new 52-week highOct 9, 2026what changed →
Is the business good?
How good a business is PCVX?
Vaxcyte, Inc. earns −72% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−72%
Return on invested capital · cost of capital 9.0% · 81 points below what the capital costs: growth destroys value
- Share count, year on year
- +6.2%
Share count, year on year · shareholders own a smaller slice than a year ago
Details›
- Free cash flow, trailing twelve months
- −$894M
- Net income, trailing twelve months
- −$1.06B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −72%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks